| Literature DB >> 34217306 |
Willemijn F C de Sonnaville1, Caroline M Speksnijder2, Nicolaas P A Zuithoff3, Daan R C Verkouteren2, Nico W Wulffraat4, Michel H Steenks2, Antoine J W P Rosenberg2.
Abstract
BACKGROUND: Recognition of temporomandibular joint (TMJ) involvement in children with juvenile idiopathic arthritis (JIA) has gained increasing attention in the past decade. The clinical assessment of mandibular range of motion characteristics is part of the recommended variables to detect TMJ involvement in children with JIA. The aim of this study was to explore explanatory variables for mandibular range of motion outcomes in children with JIA, with and without clinically established TMJ involvement, and in healthy children.Entities:
Keywords: Arthritis, juvenile; Children; Cross-sectional study; Mandibular range of motion; Mouth opening; Temporomandibular joint
Mesh:
Year: 2021 PMID: 34217306 PMCID: PMC8254997 DOI: 10.1186/s12969-021-00583-5
Source DB: PubMed Journal: Pediatr Rheumatol Online J ISSN: 1546-0096 Impact factor: 3.054
Demographics and clinical characteristics in children with JIA and in healthy children
| JIA | Healthy children | JIA with TMJ involvement | JIA without TMJ involvement | |||
|---|---|---|---|---|---|---|
| Gender (n, %) | 0.000a | 0.479a | ||||
| Male | 96 (32.2) | 88 (52.1) | 27 (29.3) | 69 (33.5) | ||
| Female | 202 (67.8) | 81 (47.9) | 65 (70.7) | 137 (66.5) | ||
| Mean age (years; mean, SD) | 12.7 (3.5) | 11.5 (3.5) | 0.000b | 15.0 (4.0) | 13.0 (6.0) | 0.000b |
| Mean weight (kg; mean, SD) | 50.7 (17.7) | 46.9 (17.3) | 0.026b | 56.5 (24.5) | 48.4 (28.2) | 0.001b |
| Mean length (cm; mean, SD) | 157.1 (18.3) | 153.0 (20.9) | 0.032b | 165.0 (22) | 160.5 (27.0) | 0.001b |
| Orthodontic treatment (n, %) | 48 (16.1) | 17 (10.1) | 0.070a | 16 (17.4) | 32 (15.5) | 0.687a |
| Medication use (n, %) | 225 (75.5) | 14 (8.3) | 0.000a | 76 (82.6) | 149 (72.3) | 0.074a |
| Clinical remission off medication | 73 (24.5) | 16 (17.4) | 55 (26.7) | 0.000a | ||
| JIA subtype (n, %) | 0.615a | |||||
| Systemic | 29 (9.7) | 11 (12.0) | 18 (8.7) | |||
| Oligoarticular, persistent | 113 (24.2) | 26 (28.3) | 87 (42.2) | |||
| Oligoarticular, extended | 32 (6.9) | 11 (12.0) | 21 (10.2) | |||
| Polyarticular, RF- | 63 (13.5) | 24 (26.1) | 39 (18.9) | |||
| Polyarticular, RF+ | 15 (3.2) | 5 (5.4) | 10 (4.9) | |||
| Enthesitis-related | 18 (3.9) | 6 (6.5) | 12 (5.8) | |||
| Psoriatic arthritis | 15 (3.2) | 5 (5.4) | 10 (4.9) | |||
| Undifferentiated | 13 (4.4) | 4 (4.3) | 9 (4.4) | |||
| Laboratory studies (n, %) | ||||||
| Positive ANA | 96 (20.6) | 67 (32.5) | 29 (31.5) | 0.645a | ||
| Positive RF | 17 (3.6) | 12 (5.8) | 5 (5.4) | 0.457b | ||
| Positive HLA-B27 | 22 (4.7) | 15 (7.3) | 7 (7.6) | 0.629a | ||
| Mean disease duration (months; mean, SD) | 62.1 (51.2) | 73.5 (56.9) | 57.1 (47.8) | 0.002b | ||
| cJADAS (n, %) | 0.000a | |||||
| 0-2 (low) | 189 (63.4) | 49 (53.3) | 140 (68.0) | |||
| 3-7 (moderate) | 61 (20.5) | 20 (21.7) | 41 (19.9) | |||
| ≥8 (high) | 42 (14.1) | 19 (20.7) | 23 (11.2) | |||
| Missing | 6 (2.0) | 4 (4.3) | 2 (1.0) | |||
| Medication use (n, %) | ||||||
| NSAIDS | 87 (29.2) | 33 (35.9) | 54 (26.2) | 0.090a | ||
| Corticosteroids | 15 (5.0) | 8 (8.7) | 9 (4.2) | 0.050a | ||
| DMARDS | 138 (46.3) | 43 (46.7) | 95 (46.2) | 0.627a | ||
| Biologicals | 88 (29.5) | 37 (40.2) | 51 (24.8) | 0.007a | ||
| No medication | 73 (24.5) | 16 (17.4) | 55 (26.7) | 0.074a | ||
| DMARDS (n, %) | 0.404a | |||||
| Methotrexate | 119 (39.9) | 33 (35.9) | 86 (41.7) | |||
| Leflunomide | 12 (4.0) | 6 (6.5) | 6 (2.9) | |||
| Azathioprine | 2 (0.7) | 1 (1.1) | 1 (0.5) | |||
| Sulphasalazine | 2 (0.7) | 1 (1.1) | 1 (0.5) | |||
| Other | 3 (1.0) | 2 (2.2) | 1 (0.5) | |||
| No DMARDS | 160 (53.7) | 49 (53.3) | 111 (53.9) | |||
| Biologicals (n, %) | 0.073a | |||||
| Adalimumab | 42 (14.1) | 14 (15.2) | 28 (13.6) | |||
| Etanercept | 23 (7.7) | 10 (10.9) | 13 (6.3) | |||
| Tocilizumab | 6 (2.0) | 3 (3.3) | 3 (1.5) | |||
| Canakinumab | 5 (1.7) | 2 (2.2) | 3 (1.5) | |||
| Golimumab | 5 (1.7) | 4 (4.3) | 1 (0.5) | |||
| Abatacept | 1 (0.3) | 1 (1.1) | 0 | |||
| Anakinra | 2 (0.7) | 1 (1.1) | 1 (0.5) | |||
| Infliximab | 1 (0.3) | 0 | 1 (0.5) | |||
| Other | 3 (1.0) | 2 (2.2) | 1 (0.5) | |||
| No Biologicals | 210 (70.5) | 55 (59.8) | 155 (75.2) | |||
| Items of the TMJ protocol score | ||||||
| | ||||||
| Problems in chewing (n, %) | 42 (14.1) | 0 (0.0) | 0.000a | 40 (43.5) | 2 (1.0) | |
| Eating slower than others (n, %) | 28 (9.4) | 5 (3.0) | 0.005a | 26 (28.3) | 2 (1.0) | |
| Biting hard food difficult (n, %) | 38 (12.8) | 0 (0.0) | 0.000a | 38 (41.3) | 0 (0.0) | |
| Pain while eating (n, %) | 54 (18.1) | 0 (0.0) | 0.000a | 49 (53.3) | 5 (2.4) | |
| Limited mouth opening (n, %) | 33 (11.1) | 1 (0.6) | 0.000a | 29 (31.5) | 4 (1.9) | |
| | ||||||
| Limited mouth opening (n, %) | 42 (14.1) | 2 (1.2) | 0.000a | 33 (35.9) | 9 (4.4) | |
| Crepitation (audible) (n, %) | 33 (11.1) | 0 (0.0) | 0.000a | 26 (28.3) | 7 (3.4) | |
| Pain AMIO (n, %) | 21 (7.0) | 0 (0.0) | 0.000a | 20 (21.7) | 1 (0.5) | |
| Deviation AMIO (>2 mm) (n, %) | 51 (17.1) | 1 (0.6) | 0.000a | 46 (50.0) | 5 (2.4) | |
| | ||||||
| Asymmetry (n, %) | 57 (19.1) | 13 (7.8) | 0.001a | 42 (45.7) | 15 (7.3) | |
| Retrognathia (n, %) | 23 (7.7) | 9 (5.4) | 0.325a | 15 (16.3) | 8 (3.9) | |
| Palpation pain | ||||||
| TMJ (n,%) | 28 (9.4) | 4 (2.4) | 0.004a | 18 (19.6) | 10 (4.9) | 0.000a |
| Masseter muscle (n,%) | 30 (10.1) | 6 (3.6) | 0.011a | 22 (23.9) | 8 (3.9) | 0.000a |
| Temporal muscle (n,%) | 13 (4.4) | 0 (0.0) | 0.006a | 11 (12.0) | 2 (1.0) | 0.000a |
AMIO active maximum interincisal mouth opening, ANA antinuclear antibody, cJADAS Clinical Juvenile Arthritis Disease Activity Score, DMARDS disease-modifying anti-rheumatic drugs, HLA-B27 human leukocyte antigen B27, JIA juvenile idiopathic arthritis, NSAIDS non-steroidal anti-inflammatory drugs, RF rheumatoid factor, SD standard deviation, TMJ temporomandibular joint, ‡TMJ screening protocol score: Additional file A
achi-squared test; bindependent sample t-test
Adjusted linear regression for mandibular range of motion in children with JIA and healthy children
| Variable | ||||||||
| JIA vs healthy children | −3.57 (− 4.85 – − 2.28) | 0.000 | −3.71 (− 5.09 – − 2.33) | 0.000 | −1.03 (1.46 – − 0.60) | 0.000 | 0.68 (0.47–0.89) | 0.000 |
| Male gender | 1.35 (2.61–0.09) | 0.035 | 0.73 (− 0.61–2.06) | 0.284 | 0.14 (− 0.29–0.56) | 0.525 | −0.15 (− 0.06–0.35) | 0.171 |
| Length | 0.14 (0.10–0.17) | 0,000 | 0.14 (0.11–0.18) | 0.000 | 0.02 (0.01–0.03) | 0.005 | 0.00 (−0.01–0.01) | 0.905 |
| Intercept | 32.51 (27.31–37.71) | 32.72 (27.29–38.14) | 7.23 (5.47–9.00) | −0.54 (−1.41 – − 0.33) | ||||
| R2 | 0.19 | 0.18 | 0.06 | 0.10 | ||||
| Variable | ||||||||
| JIA vs healthy children | −1.61 (−2.89 – −0.34) | 0.013 | −2.09 (−3.49 – − 0.70) | 0.003 | − 0.94 (− 1.40– -0.48) | 0.000 | 0.58 (0.35–0.80) | 0.000 |
| JIA with vs without TMJ involvement | −6.67 (−8.17 – −5.14) | 0.000 | −5.59 (− 7.21 – −3.97) | 0.000 | − 0.31 (− 0.86–0.25) | 0.283 | 0.36 (0.09–0.62) | 0.008 |
| Male gender | 1.12 (−0.05–2.30) | 0.060 | 0.53 (−0.75–1.80) | 0.418 | 0.13 (−0.30—0.55) | 0.564 | −0.13 (− 0.34–0.08) | 0.212 |
| Length | 0.15 (0.12–0.18) | 0.000 | 0.16 (0.12–0.19) | 0.000 | 0.02 (0.01–0.03) | 0.004 | 0.00 (−0.01–0.01) | 0.873 |
| Intercept | 28.29 (23.36–33.22) | 29.07 (23.79–34.33) | 7.04 (5.24–8.84) | −0.32 (−1.20–0.57) | ||||
| R2 | 0.30 | 0.26 | 0.07 | 0.11 | ||||
AMIO active maximum interincisal opening; CI confidence interval; JIA juvenile idiopathic arthritis; PMIO passive maximum interincisal opening; TMJ temporomandibular joint
*Discrepancy in laterotrusion was defined as the difference in laterotrusion (in millimeters) between the left and right side. TMJ involvement is proposed as a TMJ protocol score ≥ 2 in JIA patients
Mandibular range of motion in children with JIA and in healthy children
| JIA ( | Healthy ( | JIA with TMJ involvement ( | JIA without TMJ involvement | |||
|---|---|---|---|---|---|---|
| AMIO (mm; mean, SD) | 45.7 (7.6) | 49.0 (6.1) | 0.000a | 41.6 (8.7) | 47.5 (6.4) | 0.000a |
| PMIO (mm; mean, SD) | 47.4 (7.9) | 50.4 (6.1) | 0.000a | 44.1 (8.7) | 48.8 (7.0) | 0.000a |
| Protrusion (mm; mean, SD) | 7.5 (2.2) | 8.5 (2.2) | 0.000a | 7.3 (2.4) | 7.6 (2.2) | 0.462a |
| Laterotrusion left (mm; mean, SD) | 9.4 (2.1) | 9.7 (1.6) | 0.092a | 9.1 (2.2) | 9.6 (1.8) | 0.032a |
| Laterotrusion right (mm; mean, SD) | 9.4 (2.1) | 9.7 (1.6) | 0.044a | 9.0 (2.3) | 9.6 (1.8) | 0.019a |
| Discrepancy between left and right laterotrusion (mm; mean, SD) | 1.0 (1.3) | 0.3 (0.5) | 0.000a | 1.2 (1.6) | 0.6 (0.9) | 0.000a |
| Overbite (mm; mean, SD) | 2.5 (1.4) | 2.3 (1.5) | 0.127a | 2.3 (1.3) | 2.5 (1.4) | 0.181a |
| Overjet (mm; mean, SD) | 2.9 (1.7) | 3.0 (1.4) | 0.880a | 3.0 (1.8) | 2.9 (1.7) | 0.509a |
| Deviation AMIO* (n, %) | 51 (17.1) | 1 (0.6) | 0.000b | 46 (50.0) | 5 (2.4) | 0.000b |
| Deviation protrusion* (n, %) | 38 (12.8) | 0 (0.0) | 0.000b | 31 (33.7) | 7 (3.4) | 0.000b |
| Limited condylar sliding (n, %) | 17 (5.7) | 1 (0.6) | 0.006b | 14 (15.2) | 3 (1.5) | 0.000b |
a independent sample t-test; b chi-squared test
AMIO active maximum interincisal opening; cJADAS Clinical Juvenile Arthritis Disease Activity Score; DMARDS disease-modifying antirheumatic drugs; JIA juvenile idiopathic arthritis; NSAIDS non-steroidal anti-inflammatory drugs; PMIO passive maximum interincisal opening; SD: standard deviation; TMJ: temporomandibular joint;
*Deviation AMIO and protrusion were defined as mandibular midline deviation during AMIO and mandibular midline deviation during protrusion
Adjusted linear regression for mandibular range of motion variables, with correction for length and gender
| AMIO | PMIO | Protrusion | Discrepancy in laterotrusion* | |||||
|---|---|---|---|---|---|---|---|---|
| Variable | Regression coefficients | Regression coefficients | Regression coefficients | Regression coefficients | ||||
| Age | 1.30 (0.62–1.98) | 0.000 | 1.48 (0.77–2.19) | 0.000 | 0.28 (−0.06–0.51) | 0.014 | −0.01 (− 0.13–0.10) | 0.859 |
| Age squared (centered at 6) | −0.06 (− 0.12 – − 0.00) | 0.036 | − 0.07 (− 0.13 – − 0.01) | 0.018 | −0.02 (− 0.04–0.00) | 0.029 | 0.00 (− 0.01–0.01) | 0.550 |
| Length | 0.13 (0.09–0.0.16) | 0.000 | 0.13 (0.10–0.16) | 0.000 | 0.01 (0.00–0.02) | 0.039 | 0.00 (−0.00–0.01) | 0.410 |
| Male gender | 2.09 (0.82–3.36) | 0.001 | 1.52 (0.17–2.86) | 0.027 | 0.36 (−0.06–0.79) | 0.096 | −0.28 (− 0.07–0.49) | 0.009 |
| JIA subtype | 0.00 (−0.01–0.02) | 0.643 | 0.00 (− 0.01–0.02) | 0.674 | 0.00 (− 0.01–0.00) | 0.849 | − 0.00 (− 0.00–0.00) | 0.488 |
| cJADAS | −0.39 (− 0.57 – − 0.21) | 0.000 | − 0.37 (− 0.56 – − 0.18) | 0.000 | −0.04 (− 0.10–0.03) | 0.237 | 0.02 (− 0.01–0.05) | 0.178 |
| Medication use | − 2.00 (− 3.24–0.71) | 0.002 | −1.89 (− 3.22 – − 0.55) | 0.006 | −0.65 (− 1.07 – − 0.23) | 0.003 | 0.67 (0.44–0.84) | 0.000 |
| Deviation AMIO** | −6.00 (−7.90 – − 4.10) | 0.000 | −5.44 (−7.41– − 3.47) | 0.000 | − 1.15 (− 1.81 – − 0.48) | 0.001 | 0.91 (0.59–1.22) | 0.000 |
| Deviation protrusion** | −5.80 (−8.00 – − 3.59) | 0.000 | −5.40 (− 7.69 – − 3.12) | 0.000 | −1.30 (− 2.07 – − 0.53) | 0.001 | 0.96 (0.60–1.32) | 0.000 |
| TMJ palpation pain | − 4.93 (− 7.34 – − 2.52) | 0.000 | − 4.86 (− 7.34 – − 2.37) | 0.000 | −1.30 (− 2.11 – − 0.49) | 0.002 | 0.17 (− 0.24–0.57) | 0.419 |
| Masseter muscle palpation pain | − 2.23 (− 4.57–0.12) | 0.063 | 1.92 (−4.37–0.53) | 0.125 | −0.41 (− 1.20–0.37) | 0.302 | 0.03 (− 0.36–0.43) | 0.864 |
| Temporal muscle palpation pain | − 5.82 (− 9.58–2.06) | 0.002 | − 5.12 (− 8.99 – − 1.24) | 0.010 | −1.81 (− 3.10 – − 0.52) | 0.006 | 0.34 (− 0.29–0.96) | 0.288 |
| Limited condylar sliding | −9.38 (− 12.50 – − 6.27) | 0.000 | −9.70 (− 12.90 – -6.50) | 0.000 | − 2.27 (− 3.38 – -1.16) | 0.000 | 1.86 (1.36–2.37) | 0.000 |
| Orthodontic treatment | − 0.57 (− 2.41–1.27) | 0.545 | 0.34 (−2.28–1.59) | 0.727 | −0.27 (− 0.88–0.34) | 0.389 | 0.24 (− 0.07–0.55) | 0.128 |
AMIO active maximum interincisal opening; CI confidence interval; JIA juvenile idiopathic arthritis; PMIO passive maximum interincisal opening; TMJ temporomandibular joint
The adjusted model with corrections for length and gender showed the association of each variable to AMIO, PMIO, protrusion, and discrepancy in laterotrusion
*Discrepancy in laterotrusion was defined as the difference between left and right laterotrusion with correction for midline deviation. TMJ involvement is proposed as a TMJ protocol score ≥ 2 in JIA patients [5]
**Deviation AMIO and protrusion were defined as mandibular midline deviation during AMIO and mandibular midline deviation during protrusion
Fig. 1Estimated marginal means of AMIO in children with JIA and in healthy children
Fig. 2Estimated marginal means of AMIO in children with JIA with and without TMJ involvement